Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 765250 Phase 1 SAD in Healthy Volunteers
NCT05151653Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2022
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in plaque psoriasis comparing BI 765250 with Placebo (2 arms). Primary endpoint: Percentage of subjects with treatment-emergent adverse events assessed as drug-related by the investigator up to 172 days. Started Jan 2022; status: completed.
02
Drugs
BI 765250
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05151653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151653.